Ping joined H3 in 2012 and is currently Head of Discovery Research and serves as an executive leadership team member. Ping brings more than 15 years of experience in cancer research and drug discovery to H3, where he has held positions of increasing scientific and management responsibility. At H3, his group aims to discover next-generation anti-cancer medicines by targeting highly validated molecular targets based upon genomics, transcriptomics and functional data, using systematic approaches. Prior to joining H3, Ping was a group leader at Novartis Institutes for Biomedical Research, where he worked on early drug discovery and target identification and validation in oncology, leading multidisciplinary teams across multiple geographic locations. In 2010, he earned the Novartis Catalyst Award for cancer drug discovery innovation. His research has been published in leading scientific journals including Cell, Nature, Cancer Discovery, Cancer Cell and Nature Communications. Ping was also a recipient of the Endocrine Scholars Award from the Endocrine Society for his scientific achievements.
Ping received his Medical Degree (B.M.) from Shanghai Second Medical University, his Ph.D. in molecular biology from the University of Karlsruhe in Germany and postdoctoral training at the Howard Hughes Medical Institute and UC San Diego.